|
HeartWorks simulation – a breakthrough in education for cardiothoracic anesthesiologists |
 |
 |
|
Unlisted
|
|
Written by RealWire
|
|
Tuesday, 16 June 2009 20:02 |
|
The world’s first virtual heart has been developed to improve teaching of peri-operative transesophageal echocardiography (TEE) skills in the care of patients with heart disease. HeartWorks, a uniquely realistic computer-generated model of the heart and echocardiography simulator, is the result of a 4 year project driven by a team of three London-based cardiac anaesthesiologists. Recognising the power of education through simulation and its increasingly widespread adoption throughout clinical practice, the team is spearheading a pathway change in education in one of the most interesting and challenging areas of cardiac care. Now in production by Inventive Medical, a subsidiary of UCLH Charity London, HeartWorks is set to dramatically transform TEE training by university teaching hospitals worldwide. |
|
|
BMJ Group Produces Authoritative Guide And Courses On Swine Flu For Medical Professionals Across The World |
|
|
|
Unlisted
|
|
Written by RealWire
|
|
Monday, 15 June 2009 14:07 |
|
Responding to the World Health Organisation’s recent confirmation of swine flu as a pandemic, BMJ Learning, the medical education arm of the BMJ Group, has updated and revised its guide 'Influenza pandemics: why, what, and how to prepare' which covers all the information doctors need to know about pandemic flu including details of the epidemiological features and a description of the viruses involved. Three audio modules have also been published:
- 'Swine influenza: an update' has been produced in association with the UK Health Protection Agency. It reviews how doctors should be dealing with cases and suspected cases
- 'Pandemic flu: an update on ethical dilemmas' discusses the ethical dilemmas that doctors are likely to face as a pandemic worsens and answers questions about when doctors should risk their own and their families’ health to care for the sick and how to share out the available resources – drugs, ventilators, vaccines – when there’s not enough to go round
|
|
International Directory of Medical Clinics Launches |
|
|
|
Unlisted
|
|
Written by RealWire
|
|
Sunday, 14 June 2009 18:21 |
|
YourSurgeryAbroad.com offers the most comprehensive listings for the growing medical tourism market
YourSurgeryAbroad.com launches today with a directory of over 1200 providers of essential and non-essential surgery procedures making accessing international treatment centres easier for everyone. Aimed at the growing medical tourism industry, the site provides information on healthcare providers across 80 countries and 27 treatment areas, to form the most comprehensive collection of worldwide clinics on the web.
YourSurgeryAbroad.com lists specialists, clinics and brokers for free on the website, so you can be safe in the knowledge that legitimate providers are included, and not just those who have paid. |
|
Interactive Medica Launches Pharmaceutical Key Account Management SaaS Solution |
|
|
|
Unlisted
|
|
Written by RealWire
|
|
Thursday, 21 May 2009 02:35 |
|
Interactive Medica, the leading Pharma SaaS provider, today launches IM Strategic Selling, a new Software as a Service (SaaS) solution that enables promotional teams, managers and executives to identify, collaborate, plan and manage goals, strategies and activities for current and potential Key Accounts.
The changing healthcare environment that Pharmaceutical companies face today is radically different from years gone by, companies who do not embrace the more collaborative, many to many, selling approach may find themselves left out of the key relationships required to sustain the use of their products. Being able to implement and manage a Key Account Plan is a pre-requisite for any Pharmaceutical company needing to communicate with multiple decision makers and stakeholders within the Health Service. |
|
Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories and Forms Quotient Clinical, a New Strategic Business Unit |
|
|
|
Unlisted
|
|
Written by RealWire
|
|
Sunday, 17 May 2009 21:58 |
|
CAMBRIDGESHIRE, UK, 18th May 2009 – Quotient Bioresearch Limited (“Quotient”), a leading provider of drug development services, today announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient.
The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new strategic business unit within Quotient - Quotient Clinical.
With a long heritage in early development services, the Charles River Edinburgh clinical unit will combine with Pharmaceutical Profiles to offer a suite of integrated services stretching from First-in-Human (FIH) through to Phase 2a patient studies. Founded almost 20 years ago, the Edinburgh clinical unit is an industry leader in FIH studies. It was awarded Supplementary Accreditation status by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2009, demonstrating its experience and capabilities to conduct FIH trials for small molecules and biologics.
Quotient Clinical will have a workforce of approximately 160 medical, scientific and clinical staff across the two facilities in Edinburgh and Nottingham. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers.
Paul Cowan, Chairman and CEO of Quotient comments, “The creation of Quotient Clinical represents the next step in expanding the range of specialised services we offer pharmaceutical and biotech customers worldwide. We are delighted to have completed the acquisition of the Charles River Edinburgh clinical facility. With the Inveresk heritage we are bringing a world-class facility and clinical experience to Quotient Clinical.”
Quotient Clinical will be headed by Mark Egerton, formerly Chief Executive Officer of Pharmaceutical Profiles. “We will continue to build on the innovative approaches we developed at Pharmaceutical Profiles to increase the effectiveness of early development processes. Combined with the Phase I/2a expertise of the Charles River Edinburgh clinical unit, our approach to integrating flexible drug product manufacture into clinical trials will enable us to deliver significant benefits to our customers.”
For more information on Quotient Clinical, please call +44 (0)115 9749000, email
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
or visit www.quotientbioresearch.com |
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 7 of 15 |
Stocks